Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. It has the potential to significantly impact precision oncology by providing a non-invasive approach for cancer detection, monitoring, and treatment selection. However, liquid biopsy still faces challenges, including workflow standardization and broad adoption across the globe.

Join us for this webinar to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca in enhancing global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™, aimed at addressing disparities in cancer care.

Key topics:

• Transforming Cancer Care with MSK-ACCESS® powered with SOPHiA DDM™
• Closing the Gap: Reducing Inequalities in Global Cancer Care
• Strategic Alliances for Healthcare Innovation: Lessons from SOPHiA GENETICS, MSK, and AstraZeneca

BOSTON, United States and ROLLE, Switzerland, November 4, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025.

Third Quarter 2025 Financial Results

• Revenue was $19.5 million, up 23% year-over-year
• Gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year period
• Net IFRS loss was $20.0 million, up 9% year-over-year; Adjusted EBITDA loss was $10.2 million, up 8% year-over-year; Excluding the impact of elevated Swiss social charges on equity-based compensation following share price appreciation, adjusted EBITDA loss would have been $8.8 million, representing a 13% year-over-year improvement

2025 Financial Outlook

• Full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%. This compares to the prior range of $72 to $76 million.
• Adjusted EBITDA loss is now expected to be between $39 and $41 million, which includes the impact of the Swiss social charges on equity-based compensation as well as the appreciation of the Swiss Franc relative to the U.S. Dollar and its impact on our costs.

"Q3 was an excellent quarter for SOPHiA GENETICS, with revenue growth accelerating for a third consecutive quarter to 23% as new business continues to come online,” said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder. “We also demonstrated strong operating leverage as platform scalability and rigorous cost discipline resulted in a year-over-year adjusted EBITDA loss improvement when excluding the impact of elevated Swiss social charges on equity-based compensation.”

Camblong added, “Looking ahead, new business momentum remains strong. We signed an impressive cohort of 31 new customers in Q3, with an average contract value of those new signings up 180% year-over-year. We also delivered strong growth in the U.S., drove broad adoption of our Liquid Biopsy offering, and refreshed our momentum with BioPharma customers. Our AI-powered precision medicine platform, SOPHiA DDM^TM, perfectly positions us to take advantage of growing market demand and deliver future growth.”

Third Quarter 2025 Business Highlights

Expanding usage of SOPHiA DDM^TM with existing customers

• Performed a record 99,000 analyses on SOPHiA DDM^TM, representing 9% year-over-year volume growth
• Reached 488 core genomics customers as of September 30, 2025, up from 462 customers at the end of Q3 2024
• Delivered strong growth in APAC and NORAM, with 35% and 26% year-over-year analysis volume growth, respectively
• Expanded to additional application areas at multiple top-ranked institutions in Q3, including Gustave Roussy in Paris, France adding multiple new Solid Tumor applications; Tulane University in New Orleans, U.S. adopting an additional HemOnc application; and New South Wales Health Pathology in Australia adding new applications in Solid Tumors

Landing new SOPHiA DDM^TM customers to fuel future growth

• Landed an impressive 31 new customers in Q3 2025 who will implement SOPHiA DDM^TM and begin generating revenue over the next twelve months, up from 22 new customers signed in Q3 2024
• Continued to demonstrate our ability to win larger accounts as the average contract value of new signings increased by 180% year-over-year
• Signed major new customers across geographies, including the Nice University Hospital in France who is adopting MSK-ACCESS^® powered with SOPHiA DDM^TM; Clinica MEDS in Chile, who is adopting Rare Disorder applications; and the American University of Beirut, who is adopting MSK-IMPACT^® Flex powered with SOPHiA DDM^TM

Driving strong business growth in the U.S. market

• Delivered 30% year-over-year revenue growth in the U.S.
• Signed major new customers, including Baylor Scott & White Health in Texas who is adopting SOPHiA DDM^TM for HemOnc and Geisinger Health System in Pennsylvania who is adopting Pharmacogenomics applications

Accelerating growth with new applications

• Recently signed major new customers to the Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM, including Sunnybrook Health Sciences Center in Toronto, Canada and Health Services Laboratory in London
• Signed a total of 60 customers signed-to-adopt MSK-ACCESS^® powered with SOPHiA DDM^TM, with the majority expected to complete implementation and begin generating revenue over the next 3 - 6 months
• Launched SOPHiA DDM^TM Digital Twins, an AI-powered research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions

Leveraging SOPHiA DDM^TM to deliver value to BioPharma partners

• Announced major partnerships with Myriad Genetics in the U.S. and A.D.A.M. Innovations (previously “Genesis Healthcare”) in Japan to develop MSK-ACCESS^® powered with SOPHiA DDM^TM into a regulated, global companion diagnostic (CDx) assay
• Signed two major new partnerships with AstraZeneca in Q3 to (1) develop an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway and (2) leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for breast cancer

Growing sustainably by maintaining an obsession with operational excellence

• Achieved a 73.1% adjusted gross margin in Q3 by continuing to optimize compute costs and leverage the scale of the cloud-native SOPHiA DDM^TM platform
• Continuous rigorous cost discipline and improved adjusted EBITDA loss by 13% year-over-year to $8.8 million after excluding the impact of elevated Swiss social charges on equity-based compensation (an expense this quarter of $1.3 million compared to a benefit of $0.7 million in Q3 2024)
• The Company reaffirms commitment to profitable growth and expects to be approaching adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027

Earnings Call and Webcast Information

SOPHiA GENETICS will host a conference call and live webcast to discuss the third quarter 2025 results on Tuesday, November 4, 2025, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

Non-IFRS Financial Measures

Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intangible assets, share-based compensation expenses, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs and litigation expenses that are necessary for such reconciliation.

To provide investors with additional information regarding the company’s financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:

• Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;
• Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;
• Adjusted operating loss, which the company calculates as operating loss adjusted to exclude amortization of capitalized research and development expenses, amortization of intangible assets, share-based compensation expense, the non-cash portion of pensions expense paid in excess of actual contributions to match the actuarial expense, certain transaction costs and litigation expenses.
• Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, non-cash pension expenses, certain transaction costs and litigation expenses.

These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS’ results as reported under IFRS. Some of these limitations are:

• These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company’s financial liabilities;
• These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company’s financial assets;
• These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates;
• These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company’s functional currency;
• These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations;
• These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company’s business and an important part of its compensation strategy;
• These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;
• These non-IFRS measures exclude the impact of certain capital markets transaction costs.  These costs may occur from time to time in the future as needed to complete the transactions;
• These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health.  These expenses are expected to continue for the duration of the litigation and may increase in future periods;and
• Other companies, including companies in the company’s industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.

Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.

The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.

Presentation of Constant Currency Revenue

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period.

The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.

The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contact:

Kellen Sanger
IR@sophiagenetics.com
media@sophiagenetics.com

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Loss
(Amounts in USD thousands, except per share data)
(Unaudited)

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Comprehensive Loss
(Amounts in USD thousands)
(Unaudited)

SOPHiA GENETICS SA
Interim Condensed Consolidated Balance Sheets
(Amounts in USD thousands)
(Unaudited)

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Cash Flows
(Amounts in USD thousands)
(Unaudited)

SOPHiA GENETICS SA
Reconciliation of IFRS Net Loss to Adjusted EBITDA
(Amounts in USD thousands)
(Unaudited)

SOPHiA GENETICS SA
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
(Amounts in USD thousands, except for %)
(Unaudited)

SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
(Amounts in USD thousands, except percentages)
(Unaudited)

SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Operating Loss for the Period
(Amounts in USD thousands)
(Unaudited)

Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables

1. Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy.
2. Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.
3. Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
4. Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.
5. Share-based compensation expense does not include social charges on equity-based compensation of $1.3 million and $(0.7) million for the three months ended September 30, 2025 and 2024, respectively, and $1.3 million and $(0.4) million for the nine months ended September 30, 2025 and 2024, respectively.
6. Transaction costs consists of expenses incurred in connection with the Company’s shelf registration statement and the ATM program.
7. Litigation expenses consists of expenses related to the company's defense of lawsuits filed by Guardant Health.

BOSTON, MA, November 11, 2025 – Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics’ DNBSEQ-T1+ sequencing platform.  The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston.

The collaboration integrates SOPHiA GENETICS’ advanced, AI-powered applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics’ newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.

“Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling,” said Rob Tarbox, vice president of product and marketing at Complete Genomics. “By combining MSK’s rigorously validated assays, SOPHiA GENETICS’ robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers.”

“This collaboration underscores SOPHiA GENETICS’ commitment to broadening access to data-driven medicine,” said Ross Muken, President,SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”

The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to  60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.

SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows.

This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.

To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11–15, 2025 or visit www.CompleteGenomics.com and  www.SOPHiAGENETICS.com.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

Boston, MA and San Diego, CA, November 11, 2025 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine.

This collaboration integrates SOPHiA GENETICS’ AI-powered analytics platform, SOPHiA DDM™, with Element’s AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS). Together, the technologies will provide speed, scalability, and flexibility, enabling clinical researchers to turn NGS data into actionable insights within a single streamlined process. AVITI and AVITI24 users will also gain access to the full suite of SOPHiA DDM™ applications in oncology and rare disease, expanding the analytical power of their sequencing workflows.

Professor Hagay Sobol, Head of the Molecular Oncogenetics Laboratory at the Institut Paoli-Calmettes (IPC), said: “We believe that combining the Element AVITI system with the SOPHiA DDM™ Platform has the potential to transform the way our lab approaches genomic testing by seamlessly delivering highly accurate results. We expect this collaboration that pairs SOPHiA GENETICS’ powerful analytics with Element’s sequencing performance will be able to deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster.” IPC is a comprehensive cancer center in Marseille, France, specializing in cancer research, treatment, and teaching.

Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS, said: “Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local. This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies.”

Molly He, CEO and Co-Founder of Element Biosciences, said: “Pairing Element’s cutting-edge AVITI and AVITI24 systems with SOPHiA GENETICS’ powerful AI analytics is a game-changer for the genomics community. This collaboration doesn’t just streamline workflows - it redefines what’s possible in sequencing, delivering richer insights, faster results and unprecedented accessibility. Together, we’re breaking down barriers to enable the future of precision medicine and empower every lab, everywhere, to do more with their data.”

About the technology

SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize and analyze healthcare data. Since its inception, SOPHiA GENETICS has been committed to ensuring compatibility across all technologies. Through this partnership, laboratories can process datasets of any size, retain full control of their data, and scale efficiently as precision medicine adoption accelerates worldwide.

Element Biosciences’ AVITI24 5D Multiomic and AVITI next generation sequencing systems are designed to make high-performance genomics accessible to all. With its combination of accuracy, flexibility, and cost efficiency, Element empowers laboratories to scale with confidence and accelerate the researching driving precision medicine worldwide.

To learn more about the partnership or SOPHiA GENETICS, connect with the team at booth 921 at AMP in Boston, Massachusetts from November 11 – 15 or visit SOPHiAGENETICS.com.

BOSTON, United States and ROLLE, Switzerland, October 21, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.

Boston, MA and Rolle, Switzerland – October 16, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.  

SOPHiA DDM™ Digital Twins uses each patient’s unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease. Oncologists can use the virtual replica of the patient, or Digital Twin, to simulate treatment responses, disease trajectories, and survival outcomes in real time, and to explore potential treatment strategies virtually before making decisions at the bedside.

“Digital twin technology enables integrative visualization of multimodal oncologic data, revealing latent correlations across modalities. By simulating disease trajectories and therapeutic responses within a virtual environment, Digital Twins offer a framework for in silico experimentation, supporting anticipatory and individualized clinical decision-making,” said Dr. Pierre Heudel, Medical Oncologist, Centre Léon Bérard.

“This breakthrough technology represents an important step forward in helping clinicians make more informed decisions for complex cancers,” said Dr. Clara Montagut, Head of Gastrointestinal Cancer, Hospital del Mar. “Having a digital model that can simulate potential outcomes before treatment has the potential to be transformative in how we deliver future care.”

Digital Twins leverages the collective intelligence of the SOPHiA GENETICS community and a robust, multimodal, longitudinal dataset to simulate potential therapy response. The tool equips clinicians with insights derived from a broad network of global patient cases by breaking down institutional and geographic barriers and enabling clinicians to tap into a global intelligence to enhance decision making.

“Building on advances from preclinical and clinical research, digital-twin technology offers new avenues to enhance the diagnosis and management of complex diseases, including cancer. SOPHiA DDM™ Digital Twins provides clinicians and researchers with a robust, data-driven framework for hypothesis testing and may represent a meaningful step toward broader implementation of precision medicine,” noted Dr. Ernest Nadal, Director of Research and Innovation, Catalan Institute of Oncology.

Dr. Mariano Provencio Pulla, Head of the Medical Oncology Department, Puerta de Hierro University Hospital, added, “The Digital Twins concept developed by SOPHiA GENETICS is really a breakthrough in oncology. We absolutely need this approach to take full advantage of major progress that has been made in clinical care in recent years, especially in the context of pre-surgical immunotherapy for patients with non-small cell lung cancer eligible for surgery. I truly believe that it is the future of data-driven medicine.”

Powered by state-of-the-art artificial intelligence, SOPHiA DDM™ Digital Twins continuously evolves as new data becomes available, strengthening accuracy and research capabilities over time. The tool also generates synthetic data that reflects real-world disease patterns, enabling researchers to explore additional therapeutic paths and model potential outcomes before committing to a treatment strategy.

“Cancer is constantly evolving, and static snapshots are no longer enough,” said Jurgi Camblong, Ph.D., Co-Founder & CEO, SOPHiA GENETICS. “With SOPHiA DDM™ Digital Twins, we can create advanced AI models based on our broad patient network, accelerating research, sharpening clinical decisions, and turning today’s insights into tomorrow’s breakthroughs. This reflects our ambition to make data-driven medicine the global standard of care.”

SOPHiA DDM™ Digital Twins brings key features that could, in the future, reshape precision oncology:

• Personalized Treatment Insights: Help oncologists match patients to the most effective treatment strategies based on simulated outcomes, including ability to explore relevant clinical trials.
• Toxicity and Cost Avoidance: Provide insights to help physicians reduce patient exposure to ineffective therapies that drive unnecessary side effects and expenses.
• Global Knowledge, Local Impact: Leverage one of the world’s most robust, de-identified multimodal cancer datasets to help oncologists make better decisions.

This launch marks a new era in precision oncology, one where technology empowers physicians to move beyond retrospective evidence and toward forward-looking, AI-powered decision support tailored to each patient. Digital Twins is launching on the SOPHiA DDM^TM Platform for lung cancer, with more cancer types available in the coming months.

To learn more about Digital Twins or SOPHiA GENETICS, connect with the team at ESMO in Berlin, Germany from October 17 – 21 or visit SOPHiAGENETICS.COM.

BOSTON, MA - September 22, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS’s AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.

The PIK3CA/AKT1/PTEN pathway is a key molecular signaling network that regulates how cells grow and survive, and its disruption is linked to the development of many cancers, including breast and prostate cancer. The PTEN gene, when altered, can contribute to cancer development and resistance to treatment. As part of this collaboration, the companies have developed an optimized NGS solution that deploys AI agents to analyze and detect genomic mutations across the full PTEN gene. A prototype of the enhanced solution has already demonstrated improved sensitivity in its ability to detect complex mutations across the pathway.

As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS’s global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to expand patient access to precision therapies.

“Each day brings new insights that transform our understanding of cancer. Partnering with innovative biopharma leaders like AstraZeneca allows us to translate these discoveries into action for breast and prostate cancer patients worldwide, representing another step forward in our mission to democratize data-driven medicine.” said Ross Muken, President, SOPHiA GENETICS.

The expanded partnership highlights the shared commitment of SOPHiA GENETICS and AstraZeneca to drive innovation in precision oncology and to ensure that patients across the globe can benefit from advanced genomic testing and targeted treatments. To learn more, connect with SOPHiA GENETICS at the World CB & CDx Summit in Boston, MA from September 22-25, 2025

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn. 

New solution brings flexibility, efficiency, and scalability to precision oncology testing

BOSTON, MA and ROLLE, Switzerland, September 5, 2025 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced the launch of MSK-IMPACT® Flex powered with SOPHiA DDM^TM from the European Congress of Pathology. This latest innovation is designed to advance efficiencies and meaningful clinical comprehensive genomic profiling (CGP) insights. Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers.

MSK-IMPACT® Flex powered with SOPHiA DDM^TM provides a holistic view of tumor biology by enabling analysis of DNA and RNA biomarkers across all major variant classes. The solution incorporates gene expression, key signatures such as TMB, MSI, and HRD, as well as high-resolution CNV detection, allowing labs to tailor biomarker testing to each case.

“Traditional approaches to CGP often require multiple assays, leading to fragmented workflows. MSK-IMPACT® Flex powered with SOPHiA DDM^TM changes that by combining expert-designed content with the adaptive analytics enabled by SOPHiA DDM^TM. The result is a single, streamlined solution that delivers flexibility without compromise, helping labs advance precision oncology at scale.” said Philippe Menu, M.D., Ph.D, Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS.

Key advantages of MSK-IMPACT® Flex powered with SOPHiA DDM^TM include:

• Expert content design: Built on the backbone of MSK-IMPACT®, curated by Memorial Sloan Kettering Cancer Center experts, with validation in over 1000 publications.
• Comprehensive profiling: Detection of all major variant classes (SNVs, indels, CNVs, partner-agonstic fusions, exon-skipping events, gene expression) and complex signatures (TMB, MSI, HRD).
• In-depth CNV profiling: High-resolution CNV detection including whole gene amplifications/deletions and exon-level CNVs.
• Sample-level modularity: Ensures clinical relevance and cost efficiency by tailoring biomarker coverage based on each patient case.
• Operational efficiency: Tumor-only approach with robust analytical performance.
• End-to-end solution: From sample to report, with fully integrated analytics, interpretation, reporting, and data storage in SOPHiA DDM^TM.
• Maximized lab efficiency: Enabled by automated, streamlined workflows for DNA, RNA, and HRD testing.

This launch furthers SOPHiA GENETICS’ mission to democratize data-driven medicine, bringing the latest advancements in genomic testing to healthcare institutions and patients around the world.

Learn more by connecting with SOPHiA GENETICS at the European Congress of Pathology in Vienna, Austria, September 6-9, 2025, or by visiting SOPHiAGENETICS.COM  and LinkedIn.

Learn more about MSK-IMPACT® Flex powered with SOPHiA DDM™ .

Book a call to explore MSK-IMPACT® Flex powered with SOPHiA DDM™ .

About SOPHiA GENETICS  

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:  

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

Media Contact:  
media@sophiagenetics.com  

Hosted by: SOPHiA GENETICS
Presented by: Alexandre Harlé
Professor of of Biopathology, Head of Precision Medicine and Translational Research Service, Institut de Cancérologie de Lorraine (ICL), France

As precision oncology advances, clinicians and researchers require solid tumor profiling tools that go beyond traditional approaches. While most next-generation sequencing (NGS) solutions rely on DNA as input, RNA sequencing provides unique molecular insights that can inform decision making, particularly from detecting gene fusions, exon skipping, and changes in gene expression. However, practical barriers such as limited tissue availability, complex workflows, and time-consuming interpretation can challenge laboratories implementing RNA sequencing.

In this webinar, Alexandre Harlé, professor and hospital practitioner, will provide an in-depth look at expertly designed RNA NGS solutions for advanced variant detection from solid tumors, including lung and sarcoma. Harlé will share his experience of co-developing and implementing in-house, sample-to-report solutions that address the current and future needs of the Cancer Institute of Lorraine in Nancy, France.

Learning objectives:
Discover the robust analytical performance of an innovative RNA technology that detects novel (partner-agnostic) gene fusions — even when fusion partners are unknown — as well as exon skipping events and gene expression changes from small input amounts. Explore how decentralized sample-to-report workflows with fully integrated analysis, interpretation, and reporting features help accelerate turnaround times and improve operational efficiency.
Understand the value of combining targeted RNA and DNA insights to capture a more comprehensive molecular picture to support informed decision-making.

Speaker Bio:
Professor Alexandre Harlé leads the Precision Medicine and Translational Research group at the Institut de Cancérologie de Lorraine (ICL), France. His research focuses on integrating RNA sequencing and liquid biopsy approaches to better understand tumor biology and improve patient care. He has contributed to collaborative efforts developing RNA-based signatures, such as GemPred, for predicting chemotherapy response in pancreatic cancer. His team is also involved in national studies exploring circulating tumor DNA (ctDNA) for minimal residual disease detection and longitudinal monitoring. Combining clinical expertise with advanced molecular techniques, Harlé’s work aims to support the implementation of precision oncology in routine practice.

• Florian Klemm, MD, PhD – Technical Product Manager, SOPHiA GENETICS​
• Ryan Demers, MSc – Global Diagnostics Director, Lung and Liquid Biopsy Strategy, AstraZeneca​
• Persephone du Parcq, MSc, PGDip, - Deputy Operations Lead, Synnovis

MSK-ACCESS® powered with SOPHiA DDM™ offers an innovative and decentralized solution that combines MSK’s expertise in cancer genomics with the robust analytics of the SOPHiA DDM™ Platform. This application aims to address the global inequalities in comprehensive cancer care.​

Watch to hear about the collaborative efforts of SOPHiA GENETICS and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™. In this session, you will​

• Learn about the decentralized approach, technology, and the analytical performance of this liquid biopsy application.​
• Explore the journey of creating a global network for liquid biopsy testing, including efforts to reach underserved regions where access is limited.​
• Gain insights from the first hands-on experience with MSK-ACCESS® powered with SOPHiA DDM™ from one of the early-access healthcare institutions.​